Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.24), Zacks reports.
Jasper Therapeutics Stock Performance
Shares of NASDAQ:JSPR traded up $0.22 during trading on Monday, reaching $4.74. The stock had a trading volume of 158,555 shares, compared to its average volume of 290,250. The stock has a market cap of $71.20 million, a price-to-earnings ratio of -1.00 and a beta of 2.74. The firm's fifty day moving average is $4.66 and its 200 day moving average is $11.43. Jasper Therapeutics has a 52 week low of $3.13 and a 52 week high of $26.84.
Analyst Ratings Changes
Several research analysts have issued reports on JSPR shares. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Jasper Therapeutics in a report on Tuesday, March 11th. UBS Group assumed coverage on shares of Jasper Therapeutics in a research note on Thursday, February 13th. They issued a "buy" rating and a $38.00 price objective on the stock. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Jasper Therapeutics has an average rating of "Buy" and an average target price of $62.50.
View Our Latest Stock Report on Jasper Therapeutics
About Jasper Therapeutics
(
Get Free Report)
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Jasper Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jasper Therapeutics wasn't on the list.
While Jasper Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
